Peak Asset Management LLC Makes New $559,000 Investment in Edwards Lifesciences Corporation $EW

Peak Asset Management LLC acquired a new stake in Edwards Lifesciences Corporation (NYSE:EW) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 6,178 shares of the medical research company’s stock, valued at approximately $559,000.

Other hedge funds also recently made changes to their positions in the company. Hanson & Doremus Investment Management bought a new position in Edwards Lifesciences in the first quarter valued at about $25,000. JPL Wealth Management LLC bought a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at $25,000. MV Capital Management Inc. acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth $26,000. RMG Wealth Management LLC acquired a new position in Edwards Lifesciences in the first quarter valued at $26,000. Finally, TrinityBridge Ltd bought a new stake in Edwards Lifesciences during the second quarter valued at $27,000. 79.46% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have weighed in on EW. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. Evercore restated an “outperform” rating and issued a $100.00 target price on shares of Edwards Lifesciences in a research note on Monday, July 6th. UBS Group assumed coverage on Edwards Lifesciences in a research note on Tuesday, July 28th. They set a “buy” rating and a $110.00 price target on the stock. Mizuho increased their price target on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th. Finally, Citigroup boosted their price objective on Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $100.27.

Insider Activity

In other news, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the completion of the transaction, the vice president owned 98,611 shares in the company, valued at approximately $8,521,962.62. This represents a 19.01% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of Edwards Lifesciences stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the completion of the sale, the vice president directly owned 40,034 shares of the company’s stock, valued at approximately $3,684,329.02. This trade represents a 1.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 25,570 shares of company stock valued at $2,219,390 in the last 90 days. Insiders own 0.31% of the company’s stock.

Edwards Lifesciences Stock Up 0.8%

Shares of NYSE:EW opened at $90.53 on Tuesday. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $96.29. The company has a market capitalization of $52.13 billion, a PE ratio of 52.03, a price-to-earnings-growth ratio of 2.25 and a beta of 0.85. The business has a fifty day moving average price of $89.30 and a two-hundred day moving average price of $84.74. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.04. The company had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm’s revenue for the quarter was up 13.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.